TrxR Cancer Research Results

TrxR, Thioredoxin Reductase: Click to Expand ⟱
Source:
Type:
TrxR is an enzyme that reduces Trx, allowing it to perform its reducing functions. It has been shown to have a role in cancer cell metabolism and survival.
TrxR is overexpressed in various types of cancer, including breast, lung, colon, and prostate cancer.

- Part of the thioredoxin system, which regulates reactive oxygen species (ROS).
- TrxR is a major antioxidant systems that maintains the intracellular redox homeostasis.
- Inhibition causes an increase in ROS.
- TrxR is often upregulated in cancer cells to help manage increased oxidative stress, it is seen as a potential therapeutic target. Inhibiting TrxR may result in increased ROS in cancer cells, pushing them toward apoptosis.
- TrxR is a selenoprotein—meaning it incorporates the trace element selenium in the form of the amino acid selenocysteine.

TrxR inhibitors:
-Piperlongumine
-Withania somnifera (Ashwagandha)
-Parthenolide
-EGCG
-Curcumin
-Myricetin
-Gambogic Acid
Scientific Papers found: Click to Expand⟱
2649- PL,    Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence
- Review, Var, NA
AntiCan↑, ROS↑, GSH↓, TrxR↓, Trx↓, Apoptosis↑, TumCCA↑, ER Stress↑, DNAdam↑, ChemoSen↑, BioAv↓,
2942- PL,    Piperlongumine increases sensitivity of colorectal cancer cells to radiation: Involvement of ROS production via dual inhibition of glutathione and thioredoxin systems
- in-vitro, CRC, CT26 - in-vitro, CRC, DLD1 - in-vivo, CRC, CT26
ROS↑, GSH↓, TrxR↓, RadioS↑, DNAdam↑, TumCCA↑, mitResp↓, GSTs↓, OS↑,
2946- PL,    Piperlongumine, a potent anticancer phytotherapeutic: Perspectives on contemporary status and future possibilities as an anticancer agent
- Review, Var, NA
ROS↑, GSH↓, DNAdam↑, ChemoSen↑, RadioS↑, BioEnh↑, selectivity↑, BioAv↓, eff↑, p‑Akt↓, mTOR↓, GSK‐3β↓, β-catenin/ZEB1↓, HK2↓, Glycolysis↓, Cyt‑c↑, Casp9↑, Casp3↑, Casp7↑, cl‑PARP↑, TrxR↓, ER Stress↑, ATF4↝, CHOP↑, Prx4↑, NF-kB↓, cycD1/CCND1↓, CDK4↓, CDK6↓, p‑RB1↓, RAS↓, cMyc↓, TumCCA↑, selectivity↑, STAT3↓, NRF2↑, HO-1↑, PTEN↑, P-gp↓, MDR1↓, MRP1/ABCC1↓, survivin↓, Twist↓, AP-1↓, Sp1/3/4↓, STAT1↓, STAT6↓, SOX4↑, XBP-1↑, P21↑, eff↑, Inflam↓, COX2↓, IL6↓, MMP9↓, TumMeta↓, TumCI↓, ICAM-1↓, CXCR4↓, VEGF↓, angioG↓, Half-Life↝, BioAv↑,
2948- PL,    The promising potential of piperlongumine as an emerging therapeutics for cancer
- Review, Var, NA
tumCV↓, TumCP↓, TumCI↓, angioG↓, EMT↓, TumMeta↓, *hepatoP↑, *lipid-P↓, *GSH↑, cardioP↑, CycB/CCNB1↓, cycD1/CCND1↓, CDK2↓, CDK1↓, CDK4↓, CDK6↓, PCNA↓, Akt↓, mTOR↓, Glycolysis↓, NF-kB↓, IKKα↓, JAK1↓, JAK2↓, STAT3↓, ERK↓, cFos↓, Slug↓, E-cadherin↑, TOP2↓, P53↑, P21↑, Bcl-2↓, BAX↑, Casp3↑, Casp7↑, Casp8↑, p‑HER2/EBBR2↓, HO-1↑, NRF2↑, BIM↑, p‑FOXO3↓, Sp1/3/4↓, cMyc↓, EGFR↓, survivin↓, cMET↓, NQO1↑, SOD2↑, TrxR↓, MDM2↓, p‑eIF2α↑, ATF4↑, CHOP↑, MDA↑, Ki-67↓, MMP9↓, Twist↓, SOX2↓, Nanog↓, OCT4↓, N-cadherin↓, Vim↓, Snail↓, TumW↓, TumCG↓, HK2↓, RB1↓, IL6↓, IL8↓, SOD1↑, RadioS↑, ChemoSen↑, toxicity↓, Sp1/3/4↓, GSH↓, SOD↑,
2962- PL,    Synthesis of Piperlongumine Analogues and Discovery of Nuclear Factor Erythroid 2‑Related Factor 2 (Nrf2) Activators as Potential Neuroprotective Agents
- in-vitro, Nor, PC12
*GSH↑, *NQO1↑, *Trx↑, *TrxR↑, *NRF2↑, *NRF2⇅, *eff↑, *BioAv↑, *ROS↓,
2651- PLB,    Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence
- Review, Var, NA
ROS↑, TrxR↓, GSR↓, ER Stress↓, TumCCA↑, MMP↓, NF-kB↓, PI3K↓, Akt↓, mTOR↓, MKP1↓, MKP2↓, ChemoSen↑,
1983- PTL,    Targeting thioredoxin reductase by micheliolide contributes to radiosensitizing and inducing apoptosis of HeLa cells
- in-vitro, Cerv, HeLa
eff↑, TrxR↓, ROS↑, RadioS↑,
4485- Se,    Selenium stimulates the antitumour immunity: Insights to future research
- Review, NA, NA
*antiOx↑, chemoPv↑, ROS↑, Imm↑, selenoP↑, *IL2↑, *IL4↑, *TNF-α↓, *TGF-β↓, *EMT↓, Risk↓, *GPx↑, *TrxR↑,
4717- Se,    A systematic review of Selenium as a complementary treatment in cancer patients
- Review, Var, NA
*antiOx↑, eff↝, radioP↑, chemoP↑, *selenoP↑, *GPx↑, TrxR↑, *ROS↓,
3663- SFN,    Efficacy of Sulforaphane in Neurodegenerative Diseases
- Review, AD, NA - Review, Park, NA
*antiOx↑, *Inflam↓, *Half-Life↝, *NRF2↑, *NQO1↑, *HO-1↑, *TrxR↑, *ROS↓, *TNF-α↓, *IL1β↓, *IL6↓, *iNOS↓, *COX2↓, *Aβ↓, *GSH↑, *cognitive↑, *BACE↓, *HSP70/HSPA5↑, *neuroP↑, *ROS↓, *BBB↑, *MMP9↓,
3658- SFN,    Pre-Clinical Neuroprotective Evidences and Plausible Mechanisms of Sulforaphane in Alzheimer’s Disease
- Review, AD, NA
*NRF2↑, *antiOx↑, *neuroP↑, *Aβ↓, *BACE↓, *NQO1↑, *IL1β↓, *TNF-α↓, *IL6↓, *COX2↓, *iNOS↓, *NF-kB↓, *NLRP3↓, *Ca+2↓, *GSH↑, *MDA↓, *ROS↓, *SOD↑, *HO-1↑, *TrxR↑, *cognitive↑, *tau↓, *HSP70/HSPA5↑,
1459- SFN,  AF,    Auranofin Enhances Sulforaphane-Mediated Apoptosis in Hepatocellular Carcinoma Hep3B Cells through Inactivation of the PI3K/Akt Signaling Pathway
- in-vitro, Liver, Hep3B - in-vitro, Liver, HepG2
eff↑, TumCCA↑, Apoptosis↑, MMP↓, BAX↑, cl‑PARP↑, Casp3↑, Casp8↑, Casp9↑, ROS↑, eff↓, PI3K↓, Akt↓, TrxR↓, BAX↑, Bcl-2∅,
3041- SK,    Promising Nanomedicines of Shikonin for Cancer Therapy
- Review, Var, NA
Glycolysis↓, TAMS↝, BioAv↓, Half-Life↝, P21↑, ERK↓, ROS↑, GSH↓, MMP↓, TrxR↓, MMP13↓, MMP2↓, MMP9↓, SIRT2↑, Hif1a↓, PKM2↓, TumCP↓, TumMeta↓, TumCI↓,

Showing Research Papers: 51 to 63 of 63
Prev Page 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 63

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

GSH↓, 5,   GSR↓, 1,   GSTs↓, 1,   HO-1↑, 2,   MDA↑, 1,   NQO1↑, 1,   NRF2↑, 2,   Prx4↑, 1,   ROS↑, 8,   selenoP↑, 1,   SOD↑, 1,   SOD1↑, 1,   SOD2↑, 1,   Trx↓, 1,   TrxR↓, 8,   TrxR↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

mitResp↓, 1,   MMP↓, 3,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

cMyc↓, 2,   Glycolysis↓, 3,   HK2↓, 2,   PKM2↓, 1,   SIRT2↑, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 3,   p‑Akt↓, 1,   Apoptosis↑, 2,   BAX↑, 3,   Bcl-2↓, 1,   Bcl-2∅, 1,   BIM↑, 1,   Casp3↑, 3,   Casp7↑, 2,   Casp8↑, 2,   Casp9↑, 2,   Cyt‑c↑, 1,   MDM2↓, 1,   MKP1↓, 1,   MKP2↓, 1,   survivin↓, 2,  

Kinase & Signal Transduction(tgid=6) ⓘ

p‑HER2/EBBR2↓, 1,   Sp1/3/4↓, 3,  

Transcription & Epigenetics(tgid=7) ⓘ

tumCV↓, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP↑, 2,   p‑eIF2α↑, 1,   ER Stress↓, 1,   ER Stress↑, 2,   XBP-1↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 3,   P53↑, 1,   cl‑PARP↑, 2,   PCNA↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 1,   CDK2↓, 1,   CDK4↓, 2,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 2,   P21↑, 3,   RB1↓, 1,   p‑RB1↓, 1,   TumCCA↑, 5,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

cFos↓, 1,   cMET↓, 1,   EMT↓, 1,   ERK↓, 2,   p‑FOXO3↓, 1,   GSK‐3β↓, 1,   mTOR↓, 3,   Nanog↓, 1,   OCT4↓, 1,   PI3K↓, 2,   PTEN↑, 1,   RAS↓, 1,   SOX2↓, 1,   STAT1↓, 1,   STAT3↓, 2,   STAT6↓, 1,   TOP2↓, 1,   TumCG↓, 1,  

Migration(tgid=13) ⓘ

AP-1↓, 1,   E-cadherin↑, 1,   Ki-67↓, 1,   MMP13↓, 1,   MMP2↓, 1,   MMP9↓, 3,   N-cadherin↓, 1,   Slug↓, 1,   Snail↓, 1,   SOX4↑, 1,   TumCI↓, 3,   TumCP↓, 2,   TumMeta↓, 3,   Twist↓, 2,   Vim↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 2,   ATF4↑, 1,   ATF4↝, 1,   EGFR↓, 1,   Hif1a↓, 1,   TAMS↝, 1,   VEGF↓, 1,  

Barriers & Transport(tgid=15) ⓘ

P-gp↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2↓, 1,   CXCR4↓, 1,   ICAM-1↓, 1,   IKKα↓, 1,   IL6↓, 2,   IL8↓, 1,   Imm↑, 1,   Inflam↓, 1,   JAK1↓, 1,   JAK2↓, 1,   NF-kB↓, 3,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

CDK6↓, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 3,   BioAv↑, 1,   BioEnh↑, 1,   ChemoSen↑, 4,   eff↓, 1,   eff↑, 4,   eff↝, 1,   Half-Life↝, 2,   MDR1↓, 1,   MRP1/ABCC1↓, 1,   RadioS↑, 4,   selectivity↑, 2,  

Clinical Biomarkers(tgid=22) ⓘ

EGFR↓, 1,   p‑HER2/EBBR2↓, 1,   IL6↓, 2,   Ki-67↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   cardioP↑, 1,   chemoP↑, 1,   chemoPv↑, 1,   OS↑, 1,   radioP↑, 1,   Risk↓, 1,   toxicity↓, 1,   TumW↓, 1,  
Total Targets: 139

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 4,   GPx↑, 2,   GSH↑, 4,   HO-1↑, 2,   lipid-P↓, 1,   MDA↓, 1,   NQO1↑, 3,   NRF2↑, 3,   NRF2⇅, 1,   ROS↓, 5,   selenoP↑, 1,   SOD↑, 1,   Trx↑, 1,   TrxR↑, 4,  

Cell Death(tgid=5) ⓘ

iNOS↓, 2,  

Protein Folding & ER Stress(tgid=8) ⓘ

HSP70/HSPA5↑, 2,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

EMT↓, 1,  

Migration(tgid=13) ⓘ

Ca+2↓, 1,   MMP9↓, 1,   TGF-β↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2↓, 2,   IL1β↓, 2,   IL2↑, 1,   IL4↑, 1,   IL6↓, 2,   Inflam↓, 1,   NF-kB↓, 1,   TNF-α↓, 3,  

Synaptic & Neurotransmission(tgid=18) ⓘ

tau↓, 1,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 2,   BACE↓, 2,   NLRP3↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 1,   eff↑, 1,   Half-Life↝, 1,  

Clinical Biomarkers(tgid=22) ⓘ

IL6↓, 2,  

Functional Outcomes(tgid=23) ⓘ

cognitive↑, 2,   hepatoP↑, 1,   neuroP↑, 2,  
Total Targets: 40

Scientific Paper Hit Count for: TrxR, Thioredoxin Reductase
15 Auranofin
10 Curcumin
10 Piperlongumine
8 Silver-NanoParticles
4 Gold NanoParticles
3 Selenium
3 Radiotherapy/Radiation
3 Gambogic Acid
3 Sulforaphane (mainly Broccoli)
2 Copper and Cu NanoParticles
2 CUSP9
2 EGCG (Epigallocatechin Gallate)
2 Myricetin
1 Allicin (mainly Garlic)
1 Ashwagandha(Withaferin A)
1 Sorafenib (brand name Nexavar)
1 Baicalein
1 Chrysin
1 Quercetin
1 Piperine
1 5-fluorouracil
1 Plumbagin
1 Parthenolide
1 Shikonin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:825  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page